Cristiana Borselli
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Tildrakizumab as a Potential Option for Early Psoriatic Arthritis in Patients with Metabolic Comorbidities and Psoriasis: a Case Series.
Journal: Dermatology practical & conceptual
Published: June 12, 2025
Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics.
Journal: The Journal of dermatological treatment
Published: February 10, 2025
Challenging case of tinea corporis and faciei in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies.
Journal: Medical mycology case reports
Published: October 11, 2024
Prevalence of fungal colonization among patients with psoriasis in difficult-to-treat areas: impact of apremilast on mycotic burden and clinical outcomes.
Journal: Frontiers in immunology
Published: October 09, 2024
Efficacy and Safety of Apremilast in Oncological Patients with Moderate-to-Severe Plaque Psoriasis: A 5 years Retrospective Observational Study.
Journal: Clinical, cosmetic and investigational dermatology
Published: October 07, 2024
Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 11, 2024
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 06, 2023
Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology.
Journal: Expert review of clinical pharmacology
Published: October 03, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026